Astria Therapeutics Aktie

The ALPHA‑STAR study of 29 patients showed clear efficacy for Navenibart and a favorable safety profile: median reductions in HAE attack rate of 84–92% over six months and attack‑free rates of 62% and 67% in expanded cohorts. No serious adverse events or study discontinuations were reported; four non‑serious, treatment‑related events resolved quickly. Astria Therapeutics has initiated the phase‑3 ALPHA‑ORBIT study on schedule, with initial results expected in early 2027, and is conducting an open‑label long‑term extension. » Mere på de.investing.com

Astria Therapeutics has started the phase‑3 long‑term study ORBIT‑EXPANSE for Navenibart to prevent hereditary angioedema; participants from the approval‑relevant ALPHA‑ORBIT study can transition. The study includes a fixed dosing phase of at least six months followed by a flexible phase in which patients can receive quarterly or semiannual subcutaneous doses. In parallel, the company is developing the OX40 antibody STAR‑0310 with positive phase‑1a results, and H.C. Wainwright reaffirmed a “Buy” rating and raised the price target to $20.00. » Mere på de.investing.com

Astria Therapeutics reports that STAR‑0310 showed a half‑life of up to 68 days in a Phase‑1a study in healthy volunteers, dose‑proportional increases in concentrations and sustained ex‑vivo cytokine inhibition for 16–20 weeks. The drug was well tolerated at all dose levels; there were no serious treatment‑related events and only seven mild, self‑resolving adverse events. Astria plans an update to its development plans and will present the data at the EAADV congress; analyst targets range from $16 to $49. At a share price of $7.27 the balance sheet shows more cash than debt, but the company remains unprofitable. » Mere på de.investing.com